Small Molecules for Autoimmune & Inflammatory Diseases

Eydis Bio is focused on developing highly selective small molecule kinase inhibitors, particularly targeting the TAK1 protein, to address autoimmune and inflammatory diseases. Their innovative approach aims to provide safer and more effective treatment alternatives for patients, especially those who do not respond well to existing anti-TNF biologics. The company emphasizes the importance of TAK1's role in blocking TNF signaling at the site of inflammation, which is crucial for conditions such as rheumatoid arthritis, chronic pain, and systemic sclerosis. Their current pipeline includes a novel orally bioavailable TAK1 inhibitor, which is undergoing in vivo efficacy and safety evaluations.

The foundation of Eydis Bio's drug discovery efforts lies in their Universal Purinome Capture Platform (UPCP). This platform enables the identification of highly selective chemical scaffolds that target human kinases, facilitating the development of potent kinase inhibitors. The selectivity of these inhibitors is further validated through human kinome screening, ensuring their effectiveness against specific disease-driving proteins. Eydis Bio's commitment to rigorous in vivo validation using both standard and custom-designed animal models underscores their dedication to advancing therapeutic options for patients suffering from various inflammatory-mediated diseases.

United States

EydisBio is a small biotech startup based out of Durham, NC focusing on the development of a platform of small molecule therapeutics targeting a variety of diseases driven by aberrant inflammatory/autoimmune processes.

Eydis Bio

Company Details